Phathom Pharmaceuticals Files 8-K Report
Ticker: PHAT · Form: 8-K · Filed: Jul 18, 2024 · CIK: 1783183
| Field | Detail |
|---|---|
| Company | Phathom Pharmaceuticals, Inc. (PHAT) |
| Form Type | 8-K |
| Filed Date | Jul 18, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: PHAT
TL;DR
Phathom Pharma (PHAT) filed an 8-K for an 'Other Event' on July 18th. Details pending.
AI Summary
On July 18, 2024, Phathom Pharmaceuticals, Inc. filed an 8-K report. The filing indicates an 'Other Event' without specifying further details in the provided text. The company is incorporated in Delaware and its principal executive offices are located in Florham Park, New Jersey.
Why It Matters
This filing signals a material event for Phathom Pharmaceuticals, Inc., requiring disclosure to investors and the public. The specific nature of the 'Other Event' will be crucial for understanding its impact.
Risk Assessment
Risk Level: medium — The filing of an 8-K for an 'Other Event' suggests a potentially significant development that could impact the company's stock price, but the lack of specific details in the provided text creates uncertainty.
Key Numbers
- 001-39094 — SEC File Number (Identifies the company's filing history with the SEC.)
- 82-4151574 — IRS Number (Company's Employer Identification Number.)
Key Players & Entities
- Phathom Pharmaceuticals, Inc. (company) — Registrant
- July 18, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Florham Park, New Jersey (location) — Principal executive offices
FAQ
What specific event is reported under 'Other Events' in the 8-K filing?
The provided text for the 8-K filing states 'Other Events' as the item information but does not specify the nature of the event.
When was this 8-K report filed?
The report was filed on July 18, 2024.
What is Phathom Pharmaceuticals, Inc.'s state of incorporation?
Phathom Pharmaceuticals, Inc. is incorporated in Delaware.
Where are Phathom Pharmaceuticals, Inc.'s principal executive offices located?
The principal executive offices are located at 100 Campus Drive, Suite 102, Florham Park, New Jersey 07932.
What is the SEC file number for Phathom Pharmaceuticals, Inc.?
The SEC file number for Phathom Pharmaceuticals, Inc. is 001-39094.
Filing Stats: 854 words · 3 min read · ~3 pages · Grade level 15 · Accepted 2024-07-18 08:05:30
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share PHAT The Nasdaq Global Se
Filing Documents
- d812423d8k.htm (8-K) — 25KB
- 0001193125-24-180750.txt ( ) — 150KB
- phat-20240718.xsd (EX-101.SCH) — 3KB
- phat-20240718_lab.xml (EX-101.LAB) — 18KB
- phat-20240718_pre.xml (EX-101.PRE) — 11KB
- d812423d8k_htm.xml (XML) — 4KB
Forward Looking Statements
Forward Looking Statements This report contains forward-looking statements, including statements regarding patient access and continued expansion in commercial coverage with other payers; and the Company's estimates of the number of patients with Non-Erosive GERD. Investors are cautioned not to place undue reliance on these forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Phathom that any of its plans will be achieved. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in Phathom's business, including, without limitation: the Company's estimates regarding patient population and commercial coverage could prove to be inaccurate; the Company may not be able to successfully commercialize VOQUEZNA, which will depend on a number of factors including coverage and reimbursement levels from governmental authorities and health insurers as well as market acceptance by healthcare providers; the inherent risks of clinical development of vonoprazan; Phathom's dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of vonoprazan that may limit its development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; Phathom's ability to access additional capital under its term loan facility and royalty interest finance agreements is subject to certain conditions; Phathom's ability to obtain and maintain intellectual property protection and non-patent regulatory exclusivity for vonoprazan; Phathom's ability to comply with its license agreement with Takeda; and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including under the heading "Risk Factors" in the Company's most recent Annual
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PHATHOM PHARMACEUTICALS, INC. Date: July 18, 2024 By: /s/ Molly Henderson Molly Henderson Chief Financial and Business Officer